- TNFAIP2 increases macrophage response to CSF-1 through multiple effects on CSF-1 receptorRanda A Abdelnaser on 29 de October de 2025 at 10:00by inmunoadminJ Leukoc Biol. 2025 Oct 29:qiaf151. doi: 10.1093/jleuko/qiaf151. Online ahead of print. ABSTRACT The cytokine CSF-1 and its tyrosine kinase-encoding receptor CSF1R are important for the development and proliferation/survival of most tissue macrophages. We recently identified TNF-α-induced protein 2 (TNFAIP2) as a unique cellular regulator of CSF1R activation: TNFAIP2 increased the response of macrophages to … Read more
- PD-L1 directed bispecific V{delta}2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironmentby King, L. A., Veth, M., Roos, M., Scheffer, G. L., Popovic, M. A., de Gruijl, T. D., van der Vliet, H. J.Background Despite the notable success of programmed death ligand 1 (PD-L1)/programmed death 1 (PD-1) immune checkpoint blockade in cancer, resistance remains a substantial challenge. Combining immune checkpoint blockade with direct targeting of effec…
- Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinicby inmunoadminAlmost every successful anticancer treatment has been preceded by preclinical scientific breakthroughs that encouraged clinical development. However, therapeutic strategies showing promising preclinical results often fail to confirm activity in clinic…
- Acetaminophen interactions with immune checkpoint inhibitors: guilt by association?by de Lemos, M. L., de Lemos, J., Kletas, V., Latt, R., Mucovic, J.Recent studies suggest that acetaminophen may be linked to poorer long-term outcomes in patients receiving immune checkpoint inhibitors. Since acetaminophen is a widely used and essential medication for many patients with cancer, it is important to ca…
- Metagenomic next-generation sequencing unraveled the characteristic of lung microbiota in patients with checkpoint inhibitor pneumonitis: results from a prospective cohort studyby inmunoadminBackground Checkpoint inhibitor pneumonitis (CIP) is among the most lethal immune-related adverse events in patients with cancer receiving immunotherapy. This study aims to characterize the lung microbiome in patients with CIP and evaluate its diagnos…